Display options
Cite
Mojena M, Povo-Retana A, González-Ramos S, et al. Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. Front Oncol. 2018;8:328doi: 10.3389/fonc.2018.00328.
Mojena, M., Povo-Retana, A., González-Ramos, S., Fernández-García, V., Regadera, J., Zazpe, A., Artaiz, I., Martín-Sanz, P., Ledo, F., & Boscá, L. (2018). Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. Frontiers in oncology, 8328. https://doi.org/10.3389/fonc.2018.00328
Mojena, Marina, et al. "Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells." Frontiers in oncology vol. 8 (2018): 328. doi: https://doi.org/10.3389/fonc.2018.00328
Mojena M, Povo-Retana A, González-Ramos S, Fernández-García V, Regadera J, Zazpe A, Artaiz I, Martín-Sanz P, Ledo F, Boscá L. Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. Front Oncol. 2018 Aug 23;8:328. doi: 10.3389/fonc.2018.00328. eCollection 2018. PMID: 30191142; PMCID: PMC6115490.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2018 Aug 23;8:328. doi: 10.3389/fonc.2018.00328. eCollection 2018.

Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells.

Frontiers in oncology

Marina Mojena, Adrián Povo-Retana, Silvia González-Ramos, Victoria Fernández-García, Javier Regadera, Arturo Zazpe, Inés Artaiz, Paloma Martín-Sanz, Francisco Ledo, Lisardo Boscá

Affiliations

  1. Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Madrid, Spain.
  2. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares y Hepáticas y Digestivas, ISC III, Madrid, Spain.
  3. Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
  4. R&D+i Department Faes-Farma, Avda Autonomía, Leioa, Spain.

PMID: 30191142 PMCID: PMC6115490 DOI: 10.3389/fonc.2018.00328

Abstract

Melanomas are heterogeneous and aggressive tumors, and one of the worse in prognosis. Melanoma subtypes follow distinct pathways until terminal oncogenic transformation. Here, we have evaluated a series of molecules that exhibit potent cytotoxic effects over the murine and human melanoma cell lines B16F10 and MalMe-3M, respectively, both

Keywords: animal models; apoptosis; cellular lines; chemotherapy; cytotoxicity; melanoma; metastasis

References

  1. Oncogene. 2017 Jan 12;36(2):147-157 - PubMed
  2. J Invest Dermatol. 2010 Apr;130(4):1087-94 - PubMed
  3. J Immunol. 2010 Jul 1;185(1):605-14 - PubMed
  4. PLoS One. 2014 Apr 14;9(4):e94748 - PubMed
  5. EMBO J. 2018 Mar 1;37(5): - PubMed
  6. Oncotarget. 2016 Jul 12;7(28):43295-43314 - PubMed
  7. Am Surg. 2011 Feb;77(2):188-92 - PubMed
  8. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  9. N Engl J Med. 2005 Nov 17;353(20):2135-47 - PubMed
  10. Mol Cell Biol. 2003 Feb;23(4):1196-208 - PubMed
  11. J Immunol. 1999 May 15;162(10):6184-90 - PubMed
  12. Surg Oncol Clin N Am. 2006 Apr;15(2):419-37 - PubMed
  13. Front Immunol. 2018 Jun 28;9:1474 - PubMed
  14. Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1193-8 - PubMed
  15. Int J Mol Sci. 2017 Jun 10;18(6):null - PubMed
  16. Onco Targets Ther. 2017 Nov 13;10:5391-5403 - PubMed
  17. Rinsho Ketsueki. 2017;58(5):506-513 - PubMed
  18. PLoS One. 2013 Jul 15;8(7):e69593 - PubMed
  19. Clin Exp Metastasis. 2002;19(1):79-85 - PubMed
  20. Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92 - PubMed
  21. Genome Res. 2012 Feb;22(2):196-207 - PubMed
  22. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  23. FASEB J. 1999 Dec;13(15):2311-7 - PubMed
  24. J Clin Oncol. 2004 Jun 1;22(11):2092-100 - PubMed
  25. Cell. 2007 Mar 23;128(6):1119-32 - PubMed
  26. Front Oncol. 2017 Sep 27;7:233 - PubMed
  27. Clin Cancer Res. 2012 Jan 1;18(1):263-72 - PubMed
  28. Cell. 2018 May 31;173(6):1413-1425.e14 - PubMed
  29. Sci Rep. 2017 Nov 28;7(1):16517 - PubMed
  30. Cancer Cell. 2008 Apr;13(4):343-54 - PubMed
  31. Nature. 2013 Sep 12;501(7466):232-6 - PubMed
  32. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  33. Lancet Oncol. 2018 Mar;19(3):310-322 - PubMed
  34. Nature. 2017 Oct 5;550(7674):133-136 - PubMed
  35. Oncogene. 2003 May 19;22(20):3138-51 - PubMed
  36. Nat Med. 2018 Mar;24(3):262-270 - PubMed
  37. EMBO J. 2012 Jun 13;31(12):2714-36 - PubMed
  38. Cancer Res. 2003 Jul 15;63(14):3883-5 - PubMed
  39. Lancet Oncol. 2018 Feb;19(2):181-193 - PubMed
  40. Nature. 2011 Dec 21;480(7378):480-9 - PubMed
  41. Cell Death Dis. 2018 Jan 25;9(2):112 - PubMed
  42. Semin Cancer Biol. 2017 Sep 14;: - PubMed
  43. Cancer J. 2011 Sep-Oct;17(5):276 - PubMed
  44. Nat Rev Clin Oncol. 2012 Jan 10;9(2):74-6 - PubMed
  45. Cancer Res. 2013 Jul 15;73(14):4372-82 - PubMed
  46. Int J Oncol. 2017 Nov;51(5):1357-1369 - PubMed
  47. Br J Cancer. 2011 Jul 26;105(3):353-9 - PubMed

Publication Types